Back to search

Peptide record

TPDB11531

Antibacterial Antifungal Antiparasitic Hemolysis Toxicity standard
34 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB11531
Antibacterial Antifungal Antiparasitic Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 dbAMP Peptipedia Antifungipept dbAMP 3.0 i2APP APD_complete PD_Hemolysis ToxinPred 3.0
standard
No
A 34-aa standard natural multi-activity (Antibacterial, Antifungal, Antiparasitic, and other sources) peptide sequence curated from AntiBP3, dbAMP, Peptipedia, and other sources, with an available 3D structural model.
Sequence
KRFKKFFKKLKNSVKKRVKKFFRKPRVIGVTFPF
Physicochemical Analysis
C208H338N58O38
ADCEQHMWY
K
4259.34
12.90
15
0
13
+15
7.23
-0.729
57.06
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
3
Residue Composition
number
0
A
4
R
1
N
0
D
0
C
0
E
0
Q
1
G
0
H
1
I
1
L
11
K
0
M
7
F
2
P
1
S
1
T
0
W
0
Y
4
V
Amino Acid Distribution
A: 0 R: 4 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 1 L: 1 K: 11 M: 0 F: 7 P: 2 S: 1 T: 1 W: 0 Y: 0 V: 4
Chemical Descriptors
34
C208H338N58O38
4259.34
12.90
+15
7.23
-0.729
Evidence Records 28 records
Evidence 1 Activity

Activity

MIC
Antibacterial
7.7-30.8 µM

Target

Enterococcus faecalis ATCC 29212

Source & Reference

dbAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class.
active against Gram+ E. faecalis ATCC 29212 (MIC 7.7-30.8 uM), S. aureus ATCC 29213 (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), S. aureus
Evidence 2 Activity

Activity

MIC
Antibacterial
7.7 µM

Target

Staphylococcus aureus ATCC 29213

Source & Reference

dbAMP

Other

active against Gram+ E. faecalis ATCC 29212 (MIC 7.7-30.8 uM), S. aureus ATCC 29213 (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), S. aureus (MIC 7.7 uM), Gram- P. aeruginosa A
Evidence 3 Activity

Activity

MIC
Antibacterial
3.8 µM

Target

Streptococcus pyogenes clinical isolate

Source & Reference

dbAMP

Other

gainst Gram+ E. faecalis ATCC 29212 (MIC 7.7-30.8 uM), S. aureus ATCC 29213 (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), S. aureus (MIC 7.7 uM), Gram- P. aeruginosa ATCC 27853 (MIC 0.2-3.8 uM), K. pneumoniae c
Evidence 4 Activity

Activity

MIC
Antibacterial
7.7 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP

Other

7-30.8 uM), S. aureus ATCC 29213 (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), S. aureus (MIC 7.7 uM), Gram- P. aeruginosa ATCC 27853 (MIC 0.2-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9
Evidence 5 Activity

Activity

MIC
Antibacterial
0.2-3.8 µM

Target

Pseudomonas aeruginosa ATCC 27853

Source & Reference

dbAMP

Other

13 (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), S. aureus (MIC 7.7 uM), Gram- P. aeruginosa ATCC 27853 (MIC 0.2-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 (MIC 0.06-3.8 uM), and A
Evidence 6 Activity

Activity

MIC
Antibacterial
1.9 µM

Target

Klebsiella pneumoniae clinical isolate

Source & Reference

dbAMP

Other

te (MIC 3.8 uM), S. aureus (MIC 7.7 uM), Gram- P. aeruginosa ATCC 27853 (MIC 0.2-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 (MIC 0.06-3.8 uM), and A. baumannii clinical isolate (MIC 3.8 uM). Al
Evidence 7 Activity

Activity

MIC
Antibacterial
0.06-3.8 µM

Target

Escherichia coli ATCC 25922

Source & Reference

dbAMP

Other

- P. aeruginosa ATCC 27853 (MIC 0.2-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 (MIC 0.06-3.8 uM), and A. baumannii clinical isolate (MIC 3.8 uM). Also active against T. cruzi, a protozoa
Evidence 8 Activity

Activity

MIC
Antibacterial
3.8 µM

Target

A. baumannii clinical isolate

Source & Reference

dbAMP

Other

), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 (MIC 0.06-3.8 uM), and A. baumannii clinical isolate (MIC 3.8 uM). Also active against T. cruzi, a protozoan that causes Chagas' disease ( Mello et al., 20
Evidence 9 Activity

Activity

MIC
Antifungal
7.7-30.8 µM

Target

Enterococcus faecalis ATCC 29212

Source & Reference

dbAMP Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class.
active against Gram+ E. faecalis ATCC 29212 (MIC 7.7-30.8 uM), S. aureus ATCC 29213 (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), S. aureus
Evidence 10 Activity

Activity

MIC
Antifungal
7.7 µM

Target

Staphylococcus aureus ATCC 29213

Source & Reference

dbAMP Antifungipept

Other

active against Gram+ E. faecalis ATCC 29212 (MIC 7.7-30.8 uM), S. aureus ATCC 29213 (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), S. aureus (MIC 7.7 uM), Gram- P. aeruginosa A
Evidence 11 Activity

Activity

MIC
Antifungal
3.8 µM

Target

Streptococcus pyogenes clinical isolate

Source & Reference

dbAMP Antifungipept

Other

gainst Gram+ E. faecalis ATCC 29212 (MIC 7.7-30.8 uM), S. aureus ATCC 29213 (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), S. aureus (MIC 7.7 uM), Gram- P. aeruginosa ATCC 27853 (MIC 0.2-3.8 uM), K. pneumoniae c
Evidence 12 Activity

Activity

MIC
Antifungal
7.7 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP Antifungipept

Other

7-30.8 uM), S. aureus ATCC 29213 (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), S. aureus (MIC 7.7 uM), Gram- P. aeruginosa ATCC 27853 (MIC 0.2-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9
Evidence 13 Activity

Activity

MIC
Antifungal
0.2-3.8 µM

Target

Pseudomonas aeruginosa ATCC 27853

Source & Reference

dbAMP Antifungipept

Other

13 (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), S. aureus (MIC 7.7 uM), Gram- P. aeruginosa ATCC 27853 (MIC 0.2-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 (MIC 0.06-3.8 uM), and A
Evidence 14 Activity

Activity

MIC
Antifungal
1.9 µM

Target

Klebsiella pneumoniae clinical isolate

Source & Reference

dbAMP Antifungipept

Other

te (MIC 3.8 uM), S. aureus (MIC 7.7 uM), Gram- P. aeruginosa ATCC 27853 (MIC 0.2-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 (MIC 0.06-3.8 uM), and A. baumannii clinical isolate (MIC 3.8 uM). Al
Evidence 15 Activity

Activity

MIC
Antifungal
0.06-3.8 µM

Target

Escherichia coli ATCC 25922

Source & Reference

dbAMP Antifungipept

Other

- P. aeruginosa ATCC 27853 (MIC 0.2-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 (MIC 0.06-3.8 uM), and A. baumannii clinical isolate (MIC 3.8 uM). Also active against T. cruzi, a protozoa
Evidence 16 Activity

Activity

MIC
Antifungal
3.8 µM

Target

A. baumannii clinical isolate

Source & Reference

dbAMP Antifungipept

Other

), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 (MIC 0.06-3.8 uM), and A. baumannii clinical isolate (MIC 3.8 uM). Also active against T. cruzi, a protozoan that causes Chagas' disease ( Mello et al., 20
Evidence 17 Activity

Activity

MIC
Antiparasitic
7.7-30.8 µM

Target

Enterococcus faecalis ATCC 29212

Source & Reference

dbAMP 3.0

Other

Source Activity Label Source Definition
Antiparasitic
dbAMP 3.0 classified under the Anti-parasitic function class.
active against Gram+ E. faecalis ATCC 29212 (MIC 7.7-30.8 uM), S. aureus ATCC 29213 (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), S. aureus
Evidence 18 Activity

Activity

MIC
Antiparasitic
7.7 µM

Target

Staphylococcus aureus ATCC 29213

Source & Reference

dbAMP 3.0

Other

active against Gram+ E. faecalis ATCC 29212 (MIC 7.7-30.8 uM), S. aureus ATCC 29213 (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), S. aureus (MIC 7.7 uM), Gram- P. aeruginosa A
Evidence 19 Activity

Activity

MIC
Antiparasitic
3.8 µM

Target

Streptococcus pyogenes clinical isolate

Source & Reference

dbAMP 3.0

Other

gainst Gram+ E. faecalis ATCC 29212 (MIC 7.7-30.8 uM), S. aureus ATCC 29213 (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), S. aureus (MIC 7.7 uM), Gram- P. aeruginosa ATCC 27853 (MIC 0.2-3.8 uM), K. pneumoniae c
Evidence 20 Activity

Activity

MIC
Antiparasitic
7.7 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP 3.0

Other

7-30.8 uM), S. aureus ATCC 29213 (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), S. aureus (MIC 7.7 uM), Gram- P. aeruginosa ATCC 27853 (MIC 0.2-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9
Evidence 21 Activity

Activity

MIC
Antiparasitic
0.2-3.8 µM

Target

Pseudomonas aeruginosa ATCC 27853

Source & Reference

dbAMP 3.0

Other

13 (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), S. aureus (MIC 7.7 uM), Gram- P. aeruginosa ATCC 27853 (MIC 0.2-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 (MIC 0.06-3.8 uM), and A
Evidence 22 Activity

Activity

MIC
Antiparasitic
1.9 µM

Target

Klebsiella pneumoniae clinical isolate

Source & Reference

dbAMP 3.0

Other

te (MIC 3.8 uM), S. aureus (MIC 7.7 uM), Gram- P. aeruginosa ATCC 27853 (MIC 0.2-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 (MIC 0.06-3.8 uM), and A. baumannii clinical isolate (MIC 3.8 uM). Al
Evidence 23 Activity

Activity

MIC
Antiparasitic
0.06-3.8 µM

Target

Escherichia coli ATCC 25922

Source & Reference

dbAMP 3.0

Other

- P. aeruginosa ATCC 27853 (MIC 0.2-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 (MIC 0.06-3.8 uM), and A. baumannii clinical isolate (MIC 3.8 uM). Also active against T. cruzi, a protozoa
Evidence 24 Activity

Activity

MIC
Antiparasitic
3.8 µM

Target

A. baumannii clinical isolate

Source & Reference

dbAMP 3.0

Other

), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 (MIC 0.06-3.8 uM), and A. baumannii clinical isolate (MIC 3.8 uM). Also active against T. cruzi, a protozoan that causes Chagas' disease ( Mello et al., 20
Evidence 25 Activity

Activity

10% Hemolysis
Toxicity
12.5 µM
Hemolytic Cytotoxic
10% Hemolysis | 12.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Vipericidins: a novel family of cathelicidin-related peptides from the venom gland of South American pit vipers. | Amino Acids | 2014
Evidence 26 Activity

Activity

50% Cytotoxicity
Toxicity
1.6±0.11 µM
Cytotoxic
50% Cytotoxicity | 1.6±0.11 | µM | target cell: Murine macrophage cells J774

Target

Murine macrophage cells J774

Source & Reference

NA
DBAASP
Mechanistic Insights into the Leishmanicidal and Bactericidal Activities of Batroxicidin, a Cathelicidin-Related Peptide from a South American Viper ( Bothrops atrox). | J Nat Prod | 2021
Evidence 27 Activity

Activity

50% Cytotoxicity
Toxicity
21.74±4.83 µM
Cytotoxic
50% Cytotoxicity | 21.74±4.83 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Mechanistic Insights into the Leishmanicidal and Bactericidal Activities of Batroxicidin, a Cathelicidin-Related Peptide from a South American Viper ( Bothrops atrox). | J Nat Prod | 2021
Evidence 28 Hemolysis

Source & Reference

APD_complete PD_Hemolysis
APD_complete PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation.